Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Alamar Biosciences launched the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling solution, enabling the measurement of approximately 340 immune-related proteins from a single sample. The new panel expands on the previous Inflammation Panel 250, allowing researchers to detect low-abundance proteins across cancer, cardiovascular, metabolic, and autoimmune diseases.
Key figures
- Protein targets
- 340
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.